"Carbidopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.
| Descriptor ID |
D002230
|
| MeSH Number(s) |
D02.092.311.200.538.200 D02.442.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carbidopa".
Below are MeSH descriptors whose meaning is more specific than "Carbidopa".
This graph shows the total number of publications written about "Carbidopa" by people in this website by year, and whether "Carbidopa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carbidopa" by people in Profiles.
-
Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19. BMJ Case Rep. 2021 Mar 02; 14(3).
-
Outcome of Parkinson's Disease Patients Affected by COVID-19. Mov Disord. 2020 06; 35(6):905-908.
-
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin. Biochimie. 2019 May; 160:76-87.
-
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018 12; 34(12):2063-2073.
-
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. Neurodegener Dis Manag. 2018 06; 8(3):161-170.
-
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. J Neurol. 2018 May; 265(5):1124-1137.
-
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018 04; 49:60-66.
-
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord. 2017 Dec; 45:13-20.
-
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report. Acta Biomed. 2017 08 23; 88(2):190-195.
-
An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. Adv Ther. 2017 07; 34(7):1741-1752.